Capricor initiated with an Overweight at Cantor Fitzgerald ahead of Phase 3 data

Cantor Fitzgerald initiated coverage of Capricor Therapeutics with an Overweight rating and $8 price target ahead of topline Phase 3 HOPE-3 data and BLA filing in Duchenne muscular dystrophy. CAP-1002 showed significant benefit on upper limb and cardiac function vs. placebo in high unmet need non-ambulatory DMD, supporting FDA regulatory alignment, the analyst tells investors in a research note.